Disease · MONDO_0600023
idiopathic inflammatory myopathy
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. idiopathic inflammatory myopathy. Diseases, record MONDO_0600023. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0600023
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs19
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| EFGARTIGIMOD ALFA | CHEMBL4297551 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| ABATACEPT | CHEMBL1201823 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DAZUKIBART | CHEMBL4297808 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BELIMUMAB | CHEMBL1789843 | Antibody | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NIPOCALIMAB | CHEMBL4594310 | Antibody | Phase 2 | ClinicalTrials.gov and TTD | 2 | 1 | 1 | Drugs and targets |
| BARICITINIB | CHEMBL2105759 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FILGOTINIB | CHEMBL3301607 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FRONIGLUTIDE | CHEMBL5314983 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RAPCABTAGENE AUTOLEUCEL | CHEMBL5095147 | Gene | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 19
See all 19 drugsTargets12
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| FCGRT | IgG receptor FcRn large subunit p51 | 2 | IgG receptor FcRn large subunit p51 antagonist | Phase 3 | https://conductscience.org/library/genes/2217 | Drugs and targets |
| JAK1 | Tyrosine-protein kinase JAK1 | 2 | Tyrosine-protein kinase JAK1 inhibitor | Phase 2 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Tyrosine-protein kinase JAK2 | 2 | Tyrosine-protein kinase JAK2 inhibitor | Phase 2 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| TYK2 | Non-receptor tyrosine-protein kinase TYK2 | 2 | Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/7297 | Drugs and targets |
| CD80 | T-lymphocyte activation antigen CD80 | 1 | T-lymphocyte activation antigen CD80 inhibitor | Phase 3 | https://conductscience.org/library/genes/941 | Drugs and targets |
| CD86 | T-lymphocyte activation antigen CD86 | 1 | T-lymphocyte activation antigen CD86 inhibitor | Phase 3 | https://conductscience.org/library/genes/942 | Drugs and targets |
| IFNB1 | Interferon beta | 1 | Interferon beta inhibitor | Phase 3 | https://conductscience.org/library/genes/3456 | Drugs and targets |
| IL6R | Interleukin-6 receptor subunit alpha | 1 | Interleukin-6 receptor alpha subunit inhibitor | Phase 1 | https://conductscience.org/library/genes/3570 | Drugs and targets |
| JAK3 | Tyrosine-protein kinase JAK3 | 1 | Tyrosine-protein kinase JAK3 inhibitor | Phase 2 | https://conductscience.org/library/genes/3718 | Drugs and targets |
| MS4A1 | B-lymphocyte antigen CD20 | 1 | B-lymphocyte antigen CD20 binding agent | Phase 2 | https://conductscience.org/library/genes/931 | Drugs and targets |
1 to 10 of 12
See all 12 targetsTrials15
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02971683 | Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy | Phase 3 | 149 | 2021-09-17 | Polymyositis, Dermatomyositis, Autoimmune Necrotizing Myopathy, Overlap Myositis, Juvenile Myositis Above the Age of 18 | ABATACEPT | Its record names the disease | ClinicalTrials.gov |
| NCT02347891 | Belimumab in Idiopathic Inflammatory Myositis | Phase 2/3 | 17 | 2024-02-09 | Myositis | BELIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00278564 | Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases | Phase 1 | 7 | 2018-08-06 | MYOPATHY | CYCLOPHOSPHAMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT05869955 | A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) | Phase 1 | 270 | Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis | CYCLOPHOSPHAMIDE, FLUDARABINE, TOCILIZUMAB, ZOLACABTAGENE AUTOLEUCEL | Its record names the disease | ClinicalTrials.gov | |
| NCT05523167 | A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. | Phase 2/3 | 265 | Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome | EFGARTIGIMOD ALFA | Its record names the disease | ClinicalTrials.gov | |
| NCT06698796 | A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies | Phase 3 | 211 | Dermatomyositis, Polymyositis | DAZUKIBART | Its record names the disease | ClinicalTrials.gov | |
| NCT06991114 | AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. | Phase 2 | 90 | Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease | RITUXIMAB, TROCULEUCEL | Its record names the disease | ClinicalTrials.gov | |
| NCT03092180 | Optimizing Treatment on Idiopathic Inflammatory Myopathies | 60 | Idiopathic Inflammatory Myopathies | METHYLPREDNISOLONE | Open Targets' reading of its record | ClinicalTrials.gov | ||
| NCT06285539 | Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases | Phase 2 | 60 | Behcet's Disease, Idiopathic Inflammatory Myopathies, IgG4-related Disease | FILGOTINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT05833711 | Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy | Phase 2 | 39 | Dermatomyositis, Polymyositis, Idiopathic Inflammatory Myopathies | FRONIGLUTIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 15
See all 15 trialsComparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Abatacept + Standard Treatment vs Placebo + Standard Treatment: deaths from any cause | 0 of 138 | 1 of 73 | 211 | NCT02971683 | Trial comparisons |
| Abatacept + Standard Treatment vs Placebo + Standard Treatment: serious adverse events | 22 of 138 | 5 of 73 | 211 | NCT02971683 | Trial comparisons |
Abatacept + Standard Treatment vs Placebo + Standard Treatment: Number of Participants Achieving International Myositis Assessment and Clinical Studies Definition of Improvement (IMACS DOI) at Week 24 Without Rescue | 42 of 75 | 31 of 73 | 148 | NCT02971683 | Trial comparisons |
| Abatacept + Standard Treatment vs Placebo + Standard Treatment: Number of Participants Experiencing Serious Adverse Events (SAE) in the Double-Blind Period | 4 of 75 | 4 of 73 | 148 | NCT02971683 | Trial comparisons |
| Abatacept + Standard Treatment vs Placebo + Standard Treatment: Number of Participants Experiencing Adverse Events (AE) in the Double-Blind Period | 52 of 75 | 55 of 73 | 148 | NCT02971683 | Trial comparisons |
| Abatacept + Standard Treatment vs Placebo + Standard Treatment: Number of Participants Experiencing Serious Adverse Events (SAE) in the Cumulative Abatacept Period | 14 of 75 | 8 of 63 | 138 | NCT02971683 | Trial comparisons |
| Abatacept + Standard Treatment vs Placebo + Standard Treatment: Number of Participants Experiencing Adverse Events (AE) in the Cumulative Abatacept Period | 64 of 75 | 39 of 63 | 138 | NCT02971683 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0600023
GET https://conductscience.org/api/diseases/v1/MONDO_0600023/drugs